AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03888131
Drug: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
Trial: NCT03888131
Drug: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
Trial: NCT02235415
Drug: Motens® (lacidipine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02623231
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Trial: NCT04469465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02744742
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT04650984
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Trial: NCT00863239
Drug: Locteron™ (controlled-release interferon alpha 2b)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
Trial: NCT00863239
Drug: PEG-Intron™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
Trial: NCT03519152
Drug: low dose diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
Trial: NCT03020966
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen, intravenous placebo
Trial: NCT03020966
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen, oral placebo
Trial: NCT02099331
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03107416
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
Trial: NCT03652623
Drug: TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
Trial: NCT02934568
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent LEE011 or in combination with other treatments
Trial: NCT01733212
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Trial: NCT01768884
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01768884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03452475
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine tablets (20 mg/120 mg)
Trial: NCT01847131
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
Trial: NCT00331552
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00331552
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT02937584
Drug: GP MDI (PT001) 14.4 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium
Trial: NCT02937584
Drug: FF MDI (PT005) 9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol Fumarate
Trial: NCT02198001
Drug: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10
Trial: NCT00853216
Drug: Roxicodone™ tablet 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxicodone™ tablet 30 mg, single dose fasting
Trial: NCT04511923
Drug: Nebulised heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
Trial: NCT00382642
Drug: Placebo + Cognitive Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 week outpatient trial
Trial: NCT00934648
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg weekly
Trial: NCT01482390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to mericitabine orally twice daily.
Trial: NCT01101308
Drug: Reformulated OXY (Totowa) (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
Trial: NCT01101308
Drug: Reformulated OXY (Wilson) (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
Trial: NCT01695876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AMG 357 containing no active drug
Trial: NCT00263393
Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
Trial: NCT04652414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a matching placebo to prednisone.
Trial: NCT03406611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline for subcutaneous injection
Trial: NCT03159611
Drug: Tenoten for children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Trial: NCT03159611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Trial: NCT01743001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan-matching placebo oral tablet once daily
Trial: NCT02162407
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Trial: NCT02470637
Drug: SAR439065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:dry powder insulin~Route of administration: inhalation
Trial: NCT02586506
Drug: Placebo ELLIPTA inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
Trial: NCT02247648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients from control group received a shame tramadol pill on day one, two, and 3
Trial: NCT02836509
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Trial: NCT03593473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
Trial: NCT02489916
Drug: CM4307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM4307 300mg bid, each 4 week cycle
Trial: NCT02384317
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
Trial: NCT00128323
Drug: Gentian violet 0.00165% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04234204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02863718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 420mg daily
Trial: NCT00402779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet by mouth daily
Trial: NCT02624817
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description.
Trial: NCT00816023
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for IV infusion over the duration of the surgical\>\> procedure
Trial: NCT03667716
Drug: COM701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COM701 monotherapy.
Trial: NCT03667716
Drug: COM701 with Opdivo (Nivolumab).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COM701 in combination with Opdivo (Nivolumab).
Trial: NCT01955473
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
Trial: NCT01433250
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (10mg/kg i.v.).
Trial: NCT04083625
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
Trial: NCT04160546
Drug: Acetylsalicylic acid 100 MG
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
Trial: NCT04262024
Drug: cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
Trial: NCT03543072
Drug: Bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
Trial: NCT02265640
Drug: BIIL 284 BS boli
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02265640
Drug: BIIL 284 BS tablet C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00709579
Drug: RV3391A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
Trial: NCT00709579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03233880
Drug: Azithromycin 1gm
RxNorm normalized name: AZITHROMYCIN 1GM/PKT PWDR,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromicin 1 gm oral single dose
Trial: NCT00093665
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00607906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will also receive placebo capsules.
Trial: NCT01892384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00590785
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Trial: NCT00590785
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Trial: NCT00003001
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003001
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02864953
Drug: BIIB093
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02864953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03829878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for CP101
Trial: NCT04089150
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles
Trial: NCT04089150
Drug: Gemcitabine + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles
Trial: NCT00515424
Drug: RKI983
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03381833
Drug: LJPC-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, up to 20 mg per week from week 26 to 52
Trial: NCT03381833
Drug: LJPC-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, up to 20 mg per week from week 1 to 52
Trial: NCT02487407
Drug: Placebo for ODM-109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for oral administration.
Trial: NCT02398994
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02328404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo film-coated tablet of Biodal 50,000 IU
Trial: NCT01311635
Drug: AZD1981, current small-particle tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x100 mg per oral, single dose in fasted state
Trial: NCT02292732
Drug: ORTHO-NOVUM® tablet 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
Trial: NCT02292732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
Trial: NCT01311635
Drug: AZD1981, new small-particle tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x100 mg per oral, single dose
Trial: NCT01311635
Drug: AZD1981, new large-particle table
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x100 mg per oral, single dose in fasted state
Trial: NCT00296608
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00296608
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02238470
Drug: oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
Trial: NCT03145558
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care for TACE
Trial: NCT01910077
Drug: Tacrobell capsule 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule, oral, over the period I\&II(crossover)
Trial: NCT03413176
Drug: Cardiac complication induced by VEGF/VEGFR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
Trial: NCT03177629
Drug: treatment : H. pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO
Trial: NCT02758405
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml
Trial: NCT01470989
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: canakinumab 150 mg s.c., given on demand upon new flares
Trial: NCT02940002
Drug: BAY1003803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Trial: NCT03033147
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 30 minutes before root canal treatment
Trial: NCT00540618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
Trial: NCT00540618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
Trial: NCT00540618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
Trial: NCT03526861
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Trial: NCT00853970
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT02205554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine doses administered every 6 hours.
Trial: NCT00391118
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02591017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02392559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of subcutaneous placebo treatment every 4 weeks
Trial: NCT04770194
Drug: SP-8008 Prototype Capsule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04770194
Drug: SP-8008 Prototype Capsule B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04770194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03467373
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle